# US 2014/0371196 A1 · Diamino heterocyclic carboxamide compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0371196 A1
- Document ID: US20140371196A1
- Status: Published application
- Kind: A1
- Application number: 14/472,959
- Filed: 2014-08-29
- Published: 2014-12-18
- Earliest claimed: 2009-05-08
- Assignees: Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
- Applicants: Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
- Inventors: Itsuro SHIMADA; Kazuo KUROSAWA; Takahiro MATSUYA; Kazuhiko IIKUBO; Yutaka KONDOH; Akio KAMIKAWA; Hiroshi TOMIYAMA; Yoshinori IWAI
- Web page: https://patentgrep.com/patent/US20140371196A1

## CPC

- C07D 239/48: Two nitrogen atoms
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 241/26: with nitrogen atoms directly attached to ring carbon atoms
- C07D 241/28: in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 471/08: Bridged systems
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method for preventing or treating cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, EML4-ALK fusion polynucleotide-positive cancer, EML4-ALK fusion polynucleotide-positive lung cancer, or EML4-ALK fusion polynucleotide-positive non-small cell lung cancer, which comprises administering to a patient an effective amount of a compound of formula (I) or a salt thereof:
wherein the symbols are as defined below:
—X— is a group of formula (II):
A is chloro, ethyl, or isopropyl;
R1 is phenyl in which the carbon at the 4-position is substituted with —W—Y—Z and the carbon at the 3-position may be substituted with a group selected from the group consisting of halogen, R00, and —O—R00;
R00 is lower alkyl which may be substituted with one or more halogens;
—W— is a bond, piperidine-1,4-diyl, or piperazine-1,4-diyl;
—Y— is a bond;
Z is a non-aromatic heterocyclic ring which may be substituted with one or more R00;
R2 is (i) cycloalkyl which may be substituted with one or more groups selected from the group consisting of —N(lower alkyl)2, lower alkyl, —COO-lower alkyl, —OH, —COOH, —CONH—RZB, and morpholinyl, or (ii) a non-aromatic heterocyclic ring which may be substituted with one or more groups selected from the group consisting of lower alkyl, —CO-lower alkyl, oxo, —CO—RZB, and benzyl;
RZB is phenyl which may be substituted with a group selected from the group consisting of halogen and —O-lower alkyl; and
R3 is —H.

### Claim 14 (depends on 13)

The method according to claim 13, wherein in the compound of formula (I) or salt thereof R1 is phenyl in which the carbon at the 4-position is substituted with a group selected from the group consisting of 4-(4-methylpiperazin-1-yl)piperidin-1-yl, 4-(1-methylpiperidin-4-yl)piperazin-1-yl, 4-methylpiperazin-1-yl, and 4-isopropylpiperazin-1-yl, and the carbon at the 3-position may be substituted with a group selected from the group consisting of fluoro, methyl, trifluoromethyl, and methoxy.

### Claim 15 (depends on 13)

The method according to claim 13, wherein in the compound of formula (I) or salt thereof R2 is 4-hydroxycyclohexyl, 4-hydroxy-4-methylcyclohexyl, or tetrahydropyran-4-yl.

### Claim 16 (depends on 13)

The method according to claim 13, wherein said compound is:
6-ethyl-5-[(trans-4-hydroxycyclohexyl)amino]-3-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrazine-2-carboxamide,
6-ethyl-5-[(trans-4-hydroxycyclohexyl)amino]-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)pyrazine-2-carboxamide,
5-[(trans-4-hydroxycyclohexyl)amino]-6-isopropyl-3-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrazine-2-carboxamide,
6-ethyl-5-[(trans-4-hydroxycyclohexyl)amino]-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3-(trifluoromethyl)phenyl}amino)pyrazine-2-carboxamide,
6-ethyl-5-[(trans-4-hydroxycyclohexyl)amino]-3-({3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)pyrazine-2-carboxamide,
5-[(trans-4-hydroxycyclohexyl)amino]-6-isopropyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3-(trifluoromethyl)phenyl}amino)pyrazine-2-carboxamide,
6-ethyl-5-[(cis-4-hydroxy-4-methylcyclohexyl)amino]-3-({3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)pyrazine-2-carboxamide,
6-ethyl-5-[(trans-4-hydroxycyclohexyl)amino]-3-{[4-(4-isopropylpiperazin-1-yl)-3-methylphenyl]amino}pyrazine-2-carboxamide,
6-ethyl-5-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-3-({3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)pyrazine-2-carboxamide,
6-ethyl-3-({3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide,
6-chloro-5-[(trans-4-hydroxycyclohexyl)amino]-3-({3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)pyrazine-2-carboxamide,
6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide,
6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide,
6-isopropyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide,
6-ethyl-3-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide,
6-isopropyl-3-{[3-methoxy-4-(4-methylpiperazin-1-yl)phenyl]amino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide,
6-isopropyl-3-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide, or
6-ethyl-3-({3-methyl-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide.

### Claim 17 (depends on 13)

The method according to claim 13, wherein said compound is:
5-[(trans-4-hydroxycyclohexyl)amino]-6-isopropyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-3-(trifluoromethyl)phenyl}amino)pyrazine-2-carboxamide.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said compound is:
6-ethyl-5-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-3-({3-methyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)pyrazine-2-carboxamide.

### Claim 19 (depends on 13)

The method according to claim 13, wherein said compound is:
6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide.

### Claim 20 (depends on 13)

The method according to claim 13, wherein said compound is:
6-isopropyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide.

### Claim 21 (depends on 13)

The method according to claim 13, wherein said compound is:
6-ethyl-3-({3-methyl-4-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]phenyl}amino)-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide.
